Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of switching from inhaled Ventavis to
intravenous Remodulin in PAH patients who are considered to be failing inhaled Ventavis
therapy. This study is intended to provide information on the safe transition from Ventavis
to Remodulin as well as the impact intravenous Remodulin may have on overall quality of life
and treatment satisfaction compared to Ventavis.